MedPath

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Phase 3
Completed
Conditions
Chronic Plaque Psoriasis
Interventions
Registration Number
NCT04286607
Lead Sponsor
Arcutis Biotherapeutics, Inc.
Brief Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

Detailed Description

This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
333
Inclusion Criteria
  • Participants legally competent to sign and give informed consent or informed consent of legal guardian, and, if age appropriate, assent by the subject, as required by local laws

  • Males and females ages 2 years and older (inclusive)

  • Subjects with chronic plaque psoriasis who meet eligibility criteria and:

    1. Successfully completed a prior ARQ-151 cream study in psoriasis (Cohort 1) or
    2. Are naïve to treatment with ARQ-151 cream (Cohort 2)
  • Females of childbearing potential (FOCBP) must have a negative pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.

Exclusion Criteria
  • Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in a prior ARQ-151 cream study.
  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product.
  • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ARQ-151 Cream 0.3%Topical roflumilast-
Primary Outcome Measures
NameTimeMethod
Occurrence of treatment emergent AEs (TEAEs)24 weeks

The occurrence of TEAEs and the occurrence of (Serious Adverse Events) SAEs

Secondary Outcome Measures
NameTimeMethod
Achievement of a 100% reduction in PASI over time24 weeks
In subjects who achieve a 'clear' IGA time to re-starting investigational product (duration of response).24 weeks
Achievement of a 50% reduction in (Psoriasis Area Severity Index) PASI over time24 weeks
Achievement of a 90% reduction in PASI over time24 weeks
Achievement of an Investigator Global Assessment (IGA) of 'clear' or 'almost clear' over time.24 weeks
Achievement of a 75% reduction in PASI over time24 weeks
Change in Worst Itch Numeric Rating Scale) WI-NRS score over time24 weeks

Trial Locations

Locations (85)

Arcutis Biotherapeutics Clinical Site 508

🇺🇸

Los Angeles, California, United States

Arcutis Biotherapeutics Clinical Site 135

🇺🇸

Pittsburgh, Pennsylvania, United States

Arcutis Biotherapeutics Clinical Site 238

🇺🇸

Houston, Texas, United States

Arcutis Biotherapeutics Clinical Site 232

🇨🇦

Winnepeg, Manitoba, Canada

Arcutis Biotherapeutics Clinical Site 133

🇨🇦

Mississauga, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 214

🇺🇸

Indianapolis, Indiana, United States

Arcutis Biotherapeutics Clinical Site 123

🇺🇸

San Diego, California, United States

Arcutis Biotherapeutics Clinical Site 219

🇺🇸

Las Vegas, Nevada, United States

Arcutis Biotherapeutics Clinical Site 231

🇺🇸

Las Vegas, Nevada, United States

Arcutis Biotherapeutics Clinical Site 110

🇺🇸

San Antonio, Texas, United States

Arcutis Biotherapeutics Clinical Site 509

🇺🇸

Fountain Valley, California, United States

Arcutis Biotherapeutics Clinical Site 225

🇺🇸

Encino, California, United States

Arcutis Biotherapeutics Clinical Site 220

🇺🇸

San Diego, California, United States

Arcutis Biotherapeutics Clinical Site 120

🇺🇸

Irvine, California, United States

Arcutis Biotherapeutics Clinical Site 208

🇺🇸

Santa Monica, California, United States

Arcutis Biotherapeutics Clinical Site 216

🇺🇸

Fridley, Minnesota, United States

Arcutis Biotherapeutics Clinical Site 101

🇺🇸

Brighton, Massachusetts, United States

Arcutis Biotherapeutics Clinical Site 203

🇺🇸

Scottsdale, Arizona, United States

Arcutis Biotherapeutics Clinical Site 223

🇺🇸

Boynton Beach, Florida, United States

Arcutis Biotherapeutics Clinical Site 209

🇺🇸

Sweetwater, Florida, United States

Arcutis Biotherapeutics Clinical Site 213

🇺🇸

Metairie, Louisiana, United States

Arcutis Clinical Site 602

🇺🇸

Boise, Idaho, United States

Arcutis Biotherapeutics Clinical Site 237

🇺🇸

DeLand, Florida, United States

Arcutis Biotherapeutics Clinical Site 131

🇺🇸

Miami, Florida, United States

Arcutis Biotherapeutics Clinical Site 236

🇺🇸

Portsmouth, New Hampshire, United States

Arcutis Biotherapeutics Clinical Site 201

🇺🇸

North Miami Beach, Florida, United States

Arcutis Biotherapeutics Clinical Site 105

🇺🇸

Sanford, Florida, United States

Arcutis Biotherapeutics Clinical Site 218

🇨🇦

Barrie, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 106

🇨🇦

Waterloo, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 202

🇺🇸

Hialeah, Florida, United States

Arcutis Biotherapeutics Clinical Site 125

🇺🇸

Rockville, Maryland, United States

Arcutis Biotherapeutics Clinical Site 111

🇺🇸

Baton Rouge, Louisiana, United States

Arcutis Biotherapeutics Clinical Site 228

🇺🇸

Largo, Florida, United States

Arcutis Biotherapeutics Clinical Site 240

🇺🇸

Reno, Nevada, United States

Arcutis Biotherapeutics Clinical Site 118

🇺🇸

Delray Beach, Florida, United States

Arcutis Biotherapeutics Clinical Site 207

🇨🇦

Surrey, British Columbia, Canada

Arcutis Biotherapeutics Clinical Site 103

🇨🇦

London, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 116

🇺🇸

Clinton Township, Michigan, United States

Arcutis Biotherapeutics Clinical Site 210

🇺🇸

West Jordan, Utah, United States

Arcutis Biotherapeutics Clinical Site 221

🇺🇸

Murfreesboro, Tennessee, United States

Arcutis Clinical Site 601

🇩🇴

Santo Domingo, Dominican Republic

Arcutis Biotherapeutics Clinical Site 235

🇨🇦

Toronto, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 140

🇨🇦

Ottawa, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 239

🇺🇸

Beverly Hills, California, United States

Arcutis Biotherapeutics Clinical Site 127

🇺🇸

Encinitas, California, United States

Arcutis Biotherapeutics Clinical Site 112

🇺🇸

Fremont, California, United States

Arcutis Biotherapeutics Clinical Site 511

🇺🇸

Rancho Santa Margarita, California, United States

Arcutis Biotherapeutics Clinical Site 137

🇺🇸

Ocala, Florida, United States

Arcutis Biotherapeutics Clinical Site 114

🇺🇸

Plainfield, Illinois, United States

Arcutis Biotherapeutics Clinical Site 102

🇺🇸

Rolling Meadows, Illinois, United States

Arcutis Biotherapeutics Clinical Site 138

🇺🇸

Rockville, Maryland, United States

Arcutis Biotherapeutics Clinical Site 227

🇺🇸

Saint Joseph, Missouri, United States

Arcutis Biotherapeutics Clinical Site 139

🇺🇸

Reno, Nevada, United States

Arcutis Biotherapeutics Clinical Site 129

🇺🇸

East Windsor, New Jersey, United States

Arcutis Biotherapeutics Clinical Site 115

🇺🇸

High Point, North Carolina, United States

Arcutis Biotherapeutics Clinical Site 108

🇺🇸

Stony Brook, New York, United States

Arcutis Biotherapeutics Clinical Site 121

🇺🇸

New York, New York, United States

Arcutis Biotherapeutics Clinical Site 130

🇺🇸

Rochester, New York, United States

Arcutis Biotherapeutics Clinical Site 124

🇺🇸

Fairborn, Ohio, United States

Arcutis Biotherapeutics Clinical Site 128

🇺🇸

Duncansville, Pennsylvania, United States

Arcutis Biotherapeutics Clinical Site 229

🇺🇸

Broomall, Pennsylvania, United States

Arcutis Biotherapeutics Clinical Site 113

🇺🇸

Exton, Pennsylvania, United States

Arcutis Biotherapeutics Clinical Site 119

🇺🇸

Dallas, Texas, United States

Arcutis Biotherapeutics Clinical Site 206

🇺🇸

Arlington, Texas, United States

Arcutis Biotherapeutics Clinical Site 104

🇺🇸

College Station, Texas, United States

Arcutis Biotherapeutics Clinical Site 519

🇺🇸

Frisco, Texas, United States

Arcutis Biotherapeutics Clinical Site 117

🇺🇸

San Antonio, Texas, United States

Arcutis Biotherapeutics Clinical Site 132

🇨🇦

Calgary, Alberta, Canada

Arcutis Biotherapeutics Clinical Site 226

🇨🇦

Surrey, British Columbia, Canada

Arcutis Biotherapeutics Clinical Site 205

🇨🇦

Ajax, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 234

🇨🇦

Fredericton, New Brunswick, Canada

Arcutis Biotherapeutics Clinical Site 109

🇨🇦

Peterborough, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 126

🇨🇦

Québec, Quebec, Canada

Arcutis Biotherapeutics Clinical Site 204

🇨🇦

Windsor, Ontario, Canada

Arcutis Biotherapeutics Clinical Site 107

🇨🇦

Montreal, Quebec, Canada

Arcutis Biotherapeutics Clinical Site 215

🇺🇸

Santa Monica, California, United States

Arcutis Biotherapeutics Clinical Site 233

🇺🇸

Knoxville, Tennessee, United States

Arcutis Biotherapeutics Clinical Site 136

🇺🇸

San Francisco, California, United States

Arcutis Biotherapeutics Clinical Site 217

🇺🇸

Louisville, Kentucky, United States

Arcutis Biotherapeutics Clinical Site 212

🇺🇸

Detroit, Michigan, United States

Arcutis Biotherapeutics Clinical Site 222

🇺🇸

Oklahoma City, Oklahoma, United States

Arcutis Biotherapeutics Clinical Site 134

🇺🇸

Oklahoma City, Oklahoma, United States

Arcutis Biotherapeutics Clinical Site 224

🇺🇸

New Orleans, Louisiana, United States

Arcutis Biotherapeutics Clinical Site 230

🇺🇸

Richmond, Virginia, United States

Arcutis Biotherapeutics Clinical Site 211

🇺🇸

Lake Charles, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath